A randomized, controlled trial of poractant Alfa versus beractant in the treatment of preterm infants with respiratory distress syndrome

American Journal of Perinatology

Volumn 29, Issue 2, 2012, Pages 95-100

  Dizdar, Evrim Alyamac ^a   Sari, Fatma Nur ^a   Aydemir, Cumhur ^a   Oguz, Serife Suna ^a   Erdeve, Omer ^a   Uras, Nurdan ^a   Dilmen, Ugur ^a  

^a Zekai Tahir Burak Maternity and Teaching Hospital   (Turkey)

Author keywords

beractant; poractant alfa; preterm; respiratory distress syndrome; surfactant

Indexed keywords

BERACTANT; PORACTANT;

ARTICLE; CONTROLLED STUDY; EXTUBATION; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; INFANT; INFANT MORTALITY; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; MALE; OXYGEN BREATHING; PERINATAL MORBIDITY; PREMATURITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS SYNDROME; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

BIOLOGICAL AGENTS; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GESTATIONAL AGE; HEMODYNAMICS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; MALE; PHOSPHOLIPIDS; PROSPECTIVE STUDIES; PULMONARY SURFACTANTS; RESPIRATORY DISTRESS SYNDROME, NEWBORN; TREATMENT OUTCOME;

EID: 84857049227     PISSN: 07351631     EISSN: 10988785     Source Type: Journal    
DOI: 10.1055/s-0031-1295648     Document Type: Article

References (20)

1. Horbar JD, Wright LL, Soll RF., et al. National Institute of Child Health and Human Development Neonatal Research Network. A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. J Pediatr: 1993; 123 757 766 (Pubitemid 23316431)
2. Ramanathan R, Rasmussen MR, Gerstmann DR, Finer N, Sekar K.; North American Study Group. A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants. Am J Perinatol: 2004; 21 109 119 (Pubitemid 38506904)
3. Ramanathan R. Animal-derived surfactants: where are we? The evidence from randomized, controlled clinical trials. J Perinatol: 2009; 29 (Suppl 02 S38 S43
4. Rüdiger M, Tölle A, Meier W, Rüstow B. Naturally derived commercial surfactants differ in composition of surfactant lipids and in surface viscosity. Am J Physiol Lung Cell Mol Physiol: 2005; 288 L379 L383 (Pubitemid 40105377)
5. Bloom BT, Kattwinkel J, Hall RT., et al. Comparison of Infasurf (calf lung surfactant extract) to Survanta (beractant) in the treatment and prevention of respiratory distress syndrome. Pediatrics: 1997; 100 31 38 (Pubitemid 27291005)
6. Bloom BT, Clark RH.; Infasurf Survanta Clinical Trial Group. Comparison of Infasurf (calfactant) and Survanta (beractant) in the prevention and treatment of respiratory distress syndrome. Pediatrics: 2005; 116 392 399 (Pubitemid 44161465)
7. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med: 2001; 163 1723 1729 (Pubitemid 32578778)
8. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr: 1978; 92 529 534 (Pubitemid 8293290)
9. Bell MJ, Ternberg JL, Feigin RD., et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann Surg: 1978; 187 1 7
10. An international classification of retinopathy of prematurity. Pediatrics: 1984; 74 127 133
11. Gitto E, Reiter RJ, Karbownik M, Xian-Tan D, Barberi I. Respiratory distress syndrome in the newborn: role of oxidative stress. Intensive Care Med: 2001; 27 1116 1123 (Pubitemid 32710197)
12. Engle WA.; American Academy of Pediatrics Committee on Fetus and Newborn. Surfactant-replacement therapy for respiratory distress in the preterm and term neonate. Pediatrics: 2008; 121 419 432 (Pubitemid 351198470)
13. Ramanathan R. Choosing a right surfactant for respiratory distress syndrome treatment. Neonatology: 2009; 95 1 5
14. Speer CP, Gefeller O, Groneck P., et al. Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Arch Dis Child Fetal Neonatal Ed: 1995; 72 F8 F13
15. Baroutis G, Kaleyias J, Liarou T, Papathoma E, Hatzistamatiou Z, Costalos C. Comparison of three treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Eur J Pediatr: 2003; 162 476 480 (Pubitemid 36904269)
16. Malloy CA, Nicoski P, Muraskas JK. A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome. Acta Paediatr: 2005; 94 779 784 (Pubitemid 40839814)
17. Fujii AM, Patel SM, Allen R, Doros G, Guo CY, Testa S. Poractant alfa and beractant treatment of very premature infants with respiratory distress syndrome. J Perinatol: 2010; 30 665 670
18. Halliday HL. History of surfactant from 1980. Biol Neonate: 2005; 87 317 322 (Pubitemid 41094919)
19. Fujii A, Allen R, Doros G, OBrien S. Patent ductus arteriosus hemodynamics in very premature infants treated with poractant alfa or beractant for respiratory distress syndrome. J Perinatol: 2010; 30 671 676
20. Ambalavanan N, Walsh M, Bobashev G., et al. NICHD Neonatal Research Network. Intercenter differences in bronchopulmonary dysplasia or death among very low birth weight infants. Pediatrics: 2011; 127 e106 e116